Assembly Biosciences, Inc. (ASMB): Total Liabilities
$50.84M
As of 2025-12-31
$25.18M
As of 2026-06-30
+38.5%
3-year compound annual growth
+3.6%
5-year compound annual growth
+13.0%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $50.84M | -40.8% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $85.81M | -10.4% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $95.73M | +400.4% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $19.13M | -13.6% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $22.13M | -48.1% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $42.68M | -36.0% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $66.69M | +16.2% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $57.39M | +2.2% | 2020-03-04, Balance as of period end |
| 2017-12-31 | $56.18M | +208.0% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $18.24M | +21.6% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $15.00M | +18.6% | 2017-03-02, Balance as of period end |
| 2014-12-31 | $12.65M | +379.7% | 2016-03-11, Balance as of period end |
| 2013-12-31 | $2.64M | -3.9% | 2015-03-16, Balance as of period end |
| 2012-12-31 | $2.75M | +9.2% | 2014-03-31, Balance as of period end |
| 2011-12-31 | $2.51M | -16.0% | 2013-03-18, Balance as of period end |
| 2010-12-31 | $2.99M | n/a | 2012-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $50.84M | -40.8% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $107.62M | -34.3% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $177.25M | +150.5% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $390.05M | +28.1% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $20.16M | -24.3% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $52.56M | -56.6% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $9.90M | -84.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
Compare ASMB, BCYC, VRDN, ABCL side by side · Screen every company in Pharmaceutical Preparations ↗